AZD3463 ALK/IGF1R Inhibitor: Mechanisms and Evidence for Neuroblastoma Research

Executive Summary: AZD3463 is an orally bioavailable small molecule inhibitor with high affinity for ALK and IGF1R (Ki = 0.75 nM), offering selective inhibition of ALK-mediated PI3K/AKT/mTOR signaling in neuroblastoma cells (APExBIO). It effectively suppresses both wild-type and mutant ALK (F1174L, D1091N) cell lines, inducing apoptosis and autophagy at concentrations between 5–50 μM in vitro. In vivo, AZD3463 reduces tumor growth at 15 mg/kg in orthotopic xenograft mouse models. Combination with doxorubicin or temozolomide enhances cytotoxicity, supporting its use for overcoming crizotinib resistance and advancing next-generation ALK-driven cancer research (Labrèche et al. 2021).

Biological Rationale

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase with predominant neuronal expression. Aberrant ALK activation occurs in neuroblastoma, driving tumor proliferation and survival. ALK mutations such as F1174L and D1091N confer increased kinase activity and resistance to first-generation inhibitors like crizotinib (AZD3463 Mechanisms). Co-targeting IGF1R enhances blockade of redundant growth signals. The PI3K/AKT/mTOR pathway, downstream of ALK, is a critical regulator of cell survival, proliferation, and metabolism. Inhibition of this pathway induces apoptosis and autophagy, offering a rational target for neuroblastoma therapy (Labrèche et al. 2021).

Mechanism of Action of AZD3463 ALK/IGF1R inhibitor

AZD3463 is a small molecule with a molecular weight of 448.95 and the formula C24H25ClN6O. It binds ALK and IGF1R with a Ki of 0.75 nM, demonstrating high selectivity. Upon binding, AZD3463 blocks ALK-mediated phosphorylation events, inhibiting downstream PI3K/AKT/mTOR signaling. This results in reduced cell proliferation, induction of apoptosis, and autophagy in neuroblastoma models. AZD3463 is effective against both wild-type and mutant ALK, including the F1174L and D1091N variants that confer resistance to other inhibitors. The compound is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥11.22 mg/mL (APExBIO).

Evidence & Benchmarks

• AZD3463 inhibits proliferation of neuroblastoma cell lines with wild-type and activating ALK mutations (F1174L, D1091N) in vitro in a dose-dependent manner at 5–50 μM (APExBIO).
• In vivo, intraperitoneal administration of AZD3463 (15 mg/kg daily for two days) significantly reduces tumor growth in orthotopic neuroblastoma xenograft mice (Labrèche et al. 2021).
• AZD3463 demonstrates synergistic cytotoxicity when combined with doxorubicin or temozolomide in neuroblastoma models (APExBIO).
• AZD3463 overcomes resistance associated with ALK activating mutations not targeted by crizotinib (AZD3463 Mechanisms).
• PI3K/AKT/mTOR pathway inhibition by ALK/IGF1R inhibitors, such as AZD3463, induces apoptosis and autophagy in tumor cells (Labrèche et al. 2021).

Applications, Limits & Misconceptions

AZD3463 is primarily applied in neuroblastoma research, especially for models with ALK-driven oncogenesis. It is also relevant for investigating combination regimens targeting chemoresistance. The compound is a research tool and not approved for clinical use. Its solubility profile restricts use to DMSO-based preparations. AZD3463 is not suitable for applications requiring aqueous solubility or for long-term solution storage. The inhibitor is best suited for preclinical models, including cell-based assays and mouse xenograft studies (Reproducible Solutions with A8620).

Common Pitfalls or Misconceptions

• AZD3463 is not clinically approved and should not be used in human therapeutic protocols.
• It is ineffective in models where ALK is not expressed or not driving tumorigenesis.
• Water or ethanol should not be used as solvents due to insolubility; DMSO is required.
• Long-term storage of AZD3463 solutions leads to degradation; only short-term storage at -20°C is recommended.
• Synergy with chemotherapeutics is model-dependent and should not be assumed for all tumor types.

Workflow Integration & Parameters

For optimal performance, AZD3463 (A8620) from APExBIO should be prepared as a stock solution in DMSO at ≥11.22 mg/mL, with warming or sonication to enhance solubility. Solutions should be freshly prepared or stored at -20°C for several months, but not for long-term storage. Typical in vitro assay concentrations range from 5 to 50 μM, with cytotoxicity or viability endpoints measured after 24–72 hours exposure. For in vivo studies, dosing at 15 mg/kg intraperitoneally for two days yields significant tumor growth inhibition in neuroblastoma xenograft models (Optimizing Neuroblastoma Assays). This article extends prior workflow guides by providing updated evidence and mechanistic context for overcoming resistance in ALK-driven models.

For more on advanced mechanistic insight and translational strategies, see Redefining ALK-Driven Cancer Therapy—this article updates that discussion with current PI3K/AKT/mTOR data and specific usage parameters for AZD3463.

Conclusion & Outlook

AZD3463 is a high-affinity ALK/IGF1R inhibitor designed for neuroblastoma and ALK-driven cancer research. Its efficacy against wild-type and resistant ALK mutations, along with its ability to induce apoptosis and autophagy via PI3K/AKT/mTOR pathway blockade, positions it as a valuable tool for preclinical studies. Optimal use requires attention to solubility and storage protocols. AZD3463, available through APExBIO, supports next-generation approaches to resistance and combination therapy research. Ongoing studies will further clarify its translational potential and application scope in pediatric and other ALK-driven malignancies.